Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells in Adult Participants With EGFRvIII+ Glioblastoma

NCT06186401 is registered in ClinicalTrials.gov with Hideho Okada, MD, PhD as lead sponsor.

NCT NCT06186401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06186401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells in Adult Participants With EGFRvIII+ Glioblastoma
Lead sponsor
Hideho Okada, MD, PhD
Phase
Phase 1
Overall status
Recruiting
Start date
April 30, 2024
Completion date
December 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr gene mutation, glioblastoma, mgmt-unmethylated glioblastoma, recurrent glioblastoma